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Abstract: Serotonin (5-HT) is a monoamine neurotransmitter that plays an important role  
in physiological functions. 5-HT has been implicated in sleep, feeding, sexual behavior, 
temperature regulation, pain, and cognition as well as in pathological states including 
disorders connected to mood, anxiety, psychosis and pain. 5-HT1A receptors has for  
a long time been considered as an interesting target for the action of antidepressant drugs.  
It was postulated that postsynaptic 5-HT1A agonists could form a new class of antidepressant 
drugs, and mixed 5-HT1A receptor ligands/serotonin transporter (SERT) inhibitors seem to 
possess an interesting pharmacological profile. It should, however, be noted that 5-HT1A 
receptors can activate several different biochemical pathways and signal through both  
G protein-dependent and G protein-independent pathways. The variables that affect the 
multiplicity of 5-HT1A receptor signaling pathways would thus result from the summation 
of effects specific to the host cell milieu. Moreover, receptor trafficking appears different at 
pre- and postsynaptic sites. It should also be noted that the 5-HT1A receptor cooperates with 
other signal transduction systems (like the 5-HT1B or 5-HT2A/2B/2C receptors, the GABAergic 
and the glutaminergic systems), which also contribute to its antidepressant and/or anxiolytic 
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activity. Thus identifying brain specific molecular targets for 5-HT1A receptor ligands may 
result in a better targeting, raising a hope for more effective medicines for various pathologies. 
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1. Introduction 
Serotonin is a monoamine neurotransmitter that plays an important role in physiological functions, 
such as sleep, feeding, sexual behavior, temperature regulation, pain, and cognition, as well as in 
pathological states including mood disorders, anxiety disorders, psychosis, and pain disorders. 
Medications that increase the level of 5-HT, such as the selective serotonin reuptake inhibitors, are  
used as treatments of depression and anxiety. The seven 5-HT receptor classes consist of 5-HT1, 5-HT2,  
5-HT3, 5-HT4, 5-HT5, 5-HT6, 5-HT7, which are further subdivided into 14 receptor subclasses. All of 
these receptors—except for 5-HT3 receptor class, which belongs to the family of ligand-gated ionic  
channels and is permeable to Na+, K+, Ca2+ (and other cations)—belong to the superfamily of  
seven-transmembrane-domain, G protein-coupled receptors (GPCRs). For serotonin GPCRs, three main 
types of primary coupling to G proteins have been described. The 5-HT1A receptors activate Gi/Go 
proteins, the 5-HT2A receptors activate Gq/G11, and the 5-HT4, 5-HT6, and 5-HT7 activate Gs [1]. 
5-HT neurons show a number of anatomical and physiological characteristics, some of which are 
shared by noradrenergic neurons [2–4]: 
• Low number of neurons: 250,000 5-HT neurons in the human brain (out of a total of 1011). 
• Innervation of the whole neuraxis with extensive axon branching (4106 nerve terminals/mm3  
in neocortex). 
• Slow and regular discharge (pace maker neurons): strong homeostasis. 
• Neuronal activity dependent on sleep-wake cycles (REM-off neurons). 
• Very sensitive to self-inhibition through activation of 5-HT1A autoreceptors. 
• Rich neurochemistry: 14 different postsynaptic receptors. 
• Implication in a large number of physiological functions. 
• Mutual control with monoaminergic cell groups. 
5-HT neuronal activity is tightly controlled by several afferent pathways, including glutamatergic 
inputs from the forebrain (e.g., prefrontal cortex, PFC), monoaminergic, peptidergic and local 
GABAergic inputs [5]. Overall, this means that serotonergic activity and 5-HT release in the forebrain 
is very tightly controlled by a number of pre- and postsynaptic mechanisms, which have been selected 
through evolution to keep a tonic and regular activity of 5-HT neurons. As a general rule, antidepressant 
drugs aim at enhancing serotonergic activity, therefore interfering with the homeostasis of the 5-HT 
system and activating self-adaptive mechanisms that limit the full antidepressant action [2]. 
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2. 5-HT1A Receptor Distribution 
While all 5-HT receptor subtypes are localized post-synaptically on 5-HT target cells, the 5-HT1A,  
5-HT1B/D, and 5-HT2B receptors are also localized on 5-HT neurons [6]. 5-HT1A receptors are prFesent 
in high densities in limbic brain areas (hippocampus, lateral septum), cortical areas (particularly 
prefronthal and enthorinal cortex), as well as in the raphe nuclei, both dorsal and median [7]. They are 
being found in the soma, in dendrite, in some cases in the hillock of neurons, and in the cell body and 
processes of astrocytes [8]. Stimulation of 5-HT1A receptors in prefrontal cortex enhances forebrain 
catecholamine release, an effect possibly involved in the antidepressant action of the receptor agonists.  
The physiological release of 5-HT inhibits the activity of PFC pyramidal neurons due to the direct 
stimulation of 5-HT1A receptors located on the neurons (for a review see [9]). 
Presynaptically, the 5-HT1A receptor is the major somatodendritic autoreceptor on the soma and 
dendrites of serotonergic neurons, where it acts as a “brake” to inhibit the activity of the entire 5-HT 
system and is thought to delay the antidepressant response [10]. Local release of 5-HT in the raphe nuclei 
from axonal collaterals or crosstalk between different 5-HT neurons may diminish neuronal firing and 
produce a negative feedback regulation of transmitter release and may add an extra level of topographical 
specification. Consistent with their role in regulating serotonergic tone, activation of autoreceptors limits 
the initial increase of the extracellular 5-HT levels induced by selective serotonin reuptake inhibitors 
(SSRIs), and delay their therapeutic response [11,12]. 
Richardson-Jones et al. obtained transgenic mice with normal (referred as 1A-high) and low 5-HT1A 
autoreceptor levels. It was shown that compared to 1A-high mice, 1A-low mice have indistinguishable 
levels of 5-HT1A heteroreceptor expression, but displayed about 30% less autoreceptor expression than 
did the 1A-high mice. In that model, when the serotonergic system was activated, higher intrinsic  
5-HT1A autoreceptor levels resulted in lower raphe firing rate (Figure 1). The obtained data also 
suggested that, at baseline (i.e., non-stressful conditions), levels of serotonin did not differ between the 
1A-high and 1A-low mice [13,14]. 
A  
B  
Figure 1. Raphe neurons with low (A) and high (B) 5-HT1A receptor density. Mice with high 
somatodendritic 5-HT1A expression have lower basal firing rate (and elevated behavioral 
despair level). Blue dots—serotonin, red shape—SERT, green shape—5-HT1A receptor 
(according to [13,14]). 
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Postsynaptic 5-HT1A heteroreceptors are expressed in target areas receiving serotonergic innervation. 
They are located on non-serotonergic neurons, primarily in the limbic areas, such as on the dendrites and 
soma of glutamatergic pyramidal neurons, and axon terminals of GABAergic and cholinergic neurons. 
The heteroreceptors are particularly enriched in the hippocampus, where immunohistochemistry and 
radioligand binding have demonstrated high receptor levels in the stratum radiatum of CA1 and the 
granule cell layer of the dentate gyrus, and moderate levels in CA3. 5-HT1A heteroreceptors are also 
highly expressed in the entorhinal cortex, frontal cortex, and lateral septum, and moderately expressed 
in the amygdala, superior colliculus, piriform cortex, and interpeduncular nucleus, as well as in several 
hypothalamic and thalamic nuclei. Activation of 5-HT1A heteroreceptors on these distinct neurons 
mediates hyperpolarizing response to released serotonin and usually reduces neuronal excitability and 
firing [10,14]. 
Aside from 5-HT1A, the 5-HT1B receptor is also thought to serve as an autoreceptor. 5-HT1B receptors 
are expressed in the central nervous system (CNS), concentrated in the basal ganglia, striatum,  
and frontal cortex. In addition, the receptor may also act as a terminal heteroreceptor controlling  
the release of other neurotransmitters, such as acetylcholine, glutamate, dopamine, noradrenaline,  
and γ-aminobutyric acid [15,16]. The receptor is also found on cerebral arteries and other vascular 
tissues. The putative 5HT1B receptor agonist, anpirtoline, has analgesic and antidepressant-like 
properties in rodents, and 5-HT1B receptor KO mice were reported to be both highly aggressive and have 
an increased preference for alcohol [16,17]. 
Studies investigating the relationship between 5-HT1A and 5-HT1B receptors showed that 5-HT1A/1B 
knockouts had increased extracellular serotonin in the hippocampus, suggesting that the pairing of  
SSRI with 5-HT1A/1B antagonist might prove to be a potent treatment for anxiety and depression [18].  
5-HT1B receptor agonist (CP 94253) and antagonist (SB 216641) have been shown to be effective in 
preclinical models of anxiety and CP 94253 was also effective in the model of depression (forced swim 
test—FST) [19]. It was also shown that the activation of 5-HT1B heteroceptors induces antidepressant-like 
effect in mice [20]. 
3. 5-HT1A Receptor Regulated Transcription Pathways 
3.1. Adenylate Cyclase 
The primary coupling linkage of the 5-HT1A receptor (and of all 5-HT1 receptors) is to the inhibition 
of adenylate cyclase (AC) and decrease protein kinase A (PKA) activity. However, the 5-HT1A receptor 
couples to the broadest panel of second messengers of any of the 5-HT receptors [21]. This receptor has 
been reported to activate or inhibit various enzymes, channels, and kinases, and to stimulate or inhibit 
production of diverse soluble second messengers. The receptor has been found to inhibit and activate 
AC and phospholipase C (PLC), to stimulate nitric oxide synthase (NOS) and a nicotinamide adenine 
dinucleotide phosphate (NADP) oxidase-like enzyme, to activate K+ channels and high conductance 
anion channels, to inhibit Ca2+ conductance and inhibit or stimulate Ca2+ mobilization, and regulate a 
number of channels and transporters (Figure 2) [22–24]. The 5-HT1A receptor can activate protein kinase 
C (PKC), Src kinase, and mitogen-activated protein kinases (MAPKs), activate or inhibit phosphatidyl 
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inositol hydrolysis, and stimulate production of reactive oxygen species (both H2O2 and superoxide) and 
arachidonic acid [1]. 
 
Figure 2. Signal transduction pathways of the 5-HT1A receptor [22–24]. 
Despite the diversity of second messengers activated, all of the signals are almost completely  
sensitive to pertusis toxin, implicating Gi/o proteins in the signals initiated by the 5-HT1A receptor [21].  
5-HT1A heteroreceptors were shown to couple to Gαi-induced inhibition of adenylate cyclase [7,25] while 
for 5-HT1A autoreceptors the situation is not so clear. Clarke et al. [25] found that 8-hydroxy-2-(di-n-
propylamino)tetralin (8-OH-DPAT) and dipropyl-5-carboxamidotryptamine (5-HT1A receptor agonists) 
did not inhibit forskolin-stimulated adenylate cyclase activity in raphe region homogenates. On that  
basis it was accepted that the autoreceptor located in the dorsal raphe nucleus (DRN) does not exhibit 
coupling to AC-. It was found, however, that also in the raphe nucleus the 5-HT1A autoreceptor may 
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reduced the presynaptic adenylate cyclase activity in raphe nuclei, the effect being reversed by WAY 
100,635, the 5-HT1A receptor antagonist. Such behavior was not, however, observed for flibanserin and  
8-OH-DPAT (and other 5-HT1A receptor agonists), which did not exhibit coupling to AC activity in 
raphe nuclei [26,27]. Thus, those ligands exhibited regional ligand-directed receptor trafficking. 
Constitutive activity of 5-HT1A receptors has not been extensively examined. Constitutive activity  
of G-protein (Gαo) has been demonstrated in human 5-HT1A receptors stably expressed in  
transfected cell lines, as well as in the native rat 5-HT1A receptors in hippocampal membranes, as 
revealed by the inhibitory effect of inverse agonists, such as spiperone or methiotepin, on basal 
guanosine-5ʹ-O-(3-[35S]thio)-triphosphate ([35S]GTPγS) binding. In the native rat 5-HT1A receptors, 
using anti-Gαo-antibody, it was observed that spiperone and methiothepin reduced basal [35S] GTPγS 
binding to Gαo in a concentration-dependent manner to 90% of basal. The inhibition of basal [35S] GTPγS 
binding induced by spiperone and methiothepin was antagonized by WAY 100,635 (5-HT1A selective 
neutral antagonist) in a concentration-dependent manner, thus indicating that this inverse agonism was 
mediated by 5-HT1A receptors [28]. In the passive avoidance paradigm, the 8-OH-DPAT-induced 
decrease in PKA activity in the hippocampus caused increased protein phosphatase-1 activity and a 
reduction of training-induced phosphorylation of calcium/calmodulin-dependent protein kinase II 
(CaMKII), and this signaling effect was accompanied by cognitive deficits [29]. Therefore, inhibition of 
adenylate cyclase and PKA activity may mediate 5-HT1A receptor-regulated behaviors. 
3.2. GIRK and Calcium Channel 
In neurons, activation of the 5-HT1A receptor activates G protein-coupled inwardly-rectifying 
potassium channels (GIRKs) [30] in the hippocampus [31–33] and in the DRN [25,34], an action that 
profoundly hyperpolarizes neurons and decreases firing [35–38]. The activation of GIRKs is primarily 
mediated by G protein βγ subunits upon receptor activation [39–41]. The ability of 5-HT1A receptors to 
activate GIRK-induced hyperpolarizing currents allows them to have a strong effect on neuronal  
firing and excitability [34], a physiological process that may be linked to 5-HT1A receptor-regulated 
behaviors [42]. 
5-HT1A receptor activation also inhibits voltage-gated calcium channel activity to reduce calcium 
entry [43–45]. 5-HT1A receptor-mediated inhibition of Ca2+ currents in dorsal raphe was found to be 
inhibited by a peptide inhibitor of G protein βγ subunit [46]. 
3.3. ERK/MAPK Pathway 
Another major pathway of the 5-HT1A receptor is by activation of extracellular signal-regulated 
protein kinase (ERK) (or MAPK), which has been implicated in various aspects of cell proliferation  
and differentiation [47]. 5-HT1A receptors were first reported to activate ERK by phosphorylation in 
non-neuronal cells expressing 5-HT1A receptors [48,49]. This effect can be stimulated in transfected 
human 5-HT1A receptors via a pathway that shares many of the mediators of growth signals initiated by 
receptor tyrosine kinases (Figure 3). 




Figure 3. Main elements of the receptor tyrosine kinase pathway. 
The activation pathway involves pertussis toxin-sensitive G protein βγ-subunits, the nonreceptor 
tyrosine kinase (Src), tyrosine phsphorylated Shc (a molecular docking platform) and a 
phosphatidylinositol-3 kinase (PI3K) activity [22,48–51]. Moreover, the pathway appears to involve 
activation of Sos in a multimolecular complex that likely contains Shc and Grb2, p21Ras, and p74Raf−1 [21,48]. 
As in growth factor-regulated ERK activation, 5-HT1AR-induced ERK activation is mediated by the 
small GTPases Ras and Raf [22,48,51,52] and active MAPK/ERK kinase (MEK) [22]. Activation of Ras 
results in sequential activation of Raf1, which in turn phosphorylates and activates MEK 1 and 2. MEK, 
a direct uspstream protein kinase regulator of ERK, phosphorylates and activates ERK. Additionally, 
activation of ERK by 5-HT1A receptors in non-neuronal cells can be mediated by the PI3K and 
phosphatidylcholine-specific PLC in a G protein-dependent manner [22,48,49]. Despite consistent 
findings in cell systems with heterologous expression of 5-HT1A receptors, effects of 5-HT1A receptors 
on ERK activity vary in cells of neuronal origin. Consistent findings have shown that 5-HT1A receptor 
agonists rapidly but transiently increase phosphorylation of ERK in the hypothalamus [53–55], and this 
effect of 5-HT1A receptors is likely an intermediate step for 5-HT1A receptor-induced elevation of 
oxytocin, adrenocorticotropin (ACTH), and prolactin [53]. In hippocampal-derived differentiated  
HN2-5 cells, 5-HT1A agonists increase ERK phosphorylation and activity, an effect that is dependent on 
the small GTPases Ras and Raf, MEK, and calcium mobilization [23,56]. 
However, this effect of 5-HT1A receptors was not found in the primary culture of hippocampal 
neurons [57] or fetal rhombencephalic neurons [58]. In differentiated raphe neurons, 5-HT1A receptors 
are coupled to a Gβγ subunit-dependent decrease in MEK activity and ERK phosphorylation [59].  
In the rat hippocampus in vivo 5-HT1A receptor activation decreases ERK phosphorylation [54,60,61] 
and the upstream activator of ERK1/2, phospho-MEK1/2 [61]. 
The 5-HT1A receptor can regulate a number of ERK-related effectors, including activation of  
PI3K [48,49], changes in downstream protein kinases, such as the ribosomal S6 kinase (RSK) [62], 
stimulation of nuclear factor κB (NF-κB) [63], and inhibition of caspase 3 [23,56]. The pathway has 
been suggested to be involved in neuroprotective mechanisms [23]. ERK may also activate cAMP 
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and the underlying roles in stress, anxiety, and depression, suggesting that ERK signaling pathway  
may have important impact in mood-related behaviors [64]. The behavioral effects of the MEK/ERK 
signaling pathway have been reported in several studies, with MEK inhibitors causing diverse behavioral 
changes in animals, ranging from hyperactivity, reduced or increased anxiety, and depressive-like 
behavior [65–68], and MEK inhibitors also block the behavioral effect of antidepressants [69].  
It was also demonstrated that the activity of ERK1/2 decreased in the occipital cortex of depressed 
suicide victims. The MEK/ERK signaling pathways were shown to be involved in transcriptional 
activation and protein synthesis of neuronal survival and neuroplasticity in depression. Importantly, it 
was shown that an acute blockade of the MAPK signaling produced a depressive-like phenotype and 
blocked behavioral actions of antidepressants. Moreover, activation of the MAPK/ERK pathway could 
inhibit apoptosis by inducing the phosphorylation of Bad (a proapoptotic protein) and increasing the 
expression of antiapoptotic Bcl-2. Given these observations, MAPK/ERK pathway may be involved in 
the depression etiopathogenesis and effectiveness of antidepressants [70]. 
3.4. PI3K and Akt Pathway 
Another growth factor-regulated signaling pathway, the PI3K and Akt pathway, can also be regulated 
by 5-HT1A receptors. When tyrosine kinase receptors are activated by growth factors, they recruit PI3K 
to activate phosphoinositide-dependent kinase (PDK), which phosphorylates and activates Akt [71].  
The PI3-K/Akt pathway is classically implicated in the regulation of cell growth, survival, proliferation, 
and movement [72]. In the mammalian brain, in addition to its functions in neuronal survival and 
differentiation, several studies have implicated the PI3K/Akt pathway in synaptic plasticity, learning, 
and memory. It was shown that activation of PI3K/Akt was required for the expression of long-term 
potentiation (LTP) in the dentate gyrus and CA1 region of the hippocampus. Moreover, pharmacological 
inhibition of PI3K/Akt significantly impaired the inhibitory avoidance, spatial learning, consolidation, 
retrieval, and extinction of fear-associated memory [70]. Akt dysregulation has been linked to numerous 
metabolic diseases including diabetes and obesity, and mental disorders such as schizophrenia and drug 
abuse. Aberrant Akt function has been progressively linked to a growing number of brain disease states. 
It has been proposed that Akt may represent a molecular link between diseases driven by insulin 
resistance (e.g., diabetes) and disorders associated with central monoaminergic disturbances, including 
depression, schizophrenia and drug abuse [73]. 
The serotonin receptor class 1 has been reported to activate Erk1/2 and Akt in various cell types [74]. 
Activation of 5-HT1A receptor in Chinese hamster ovary (CHO) cells resulted in PI3K dependent 
increased phosphorylation of ERK1/2 and Akt [22]. 5-HT dose-dependently induced activation of 
Erk1/2 in PC-3, Du145, and LNCaP prostate cancer (PC) cells. Similarly, 5-HT induced phosphorylation 
of Akt in these cell lines. The action of 5-HT was inhibited to varying degrees by inhibitors of MAPK 
(U0126) and PI3K (LY294002), as well as by a 5-HT1A receptor antagonist (NAN-190). In addition to 
proliferation, 5-HT induced migration of PC-3 and Du145 cells, which were alleviated by the 
aforementioned inhibitors. Regulation of Akt by 5-HT1A receptors in the mammalian brain has not yet 
been reported; however, some indirect evidence does suggest an effect of 5-HT1A receptors in regulating 
Akt [24]. It has been shown that 5-HT1/7 receptor-selective agonists (5-carboxamidotryptamine and  
8-OH-DPAT) can activate Akt in hippocampal primary cultures with similar efficacy and potency as  
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5-HT, the effects being completely inhibited by the selective 5-HT1A receptor antagonists (p-MPPI and 
WAY-100635) [57]. It was demonstrated that fluoxetine significantly upregulated expression of the 
phosphorylated-AKT and ERK1/2 proteins in neural stem cells derived from rats. Besides, expression 
of phosphorylated-Akt and phosphorylated-ERK1/2 in fluoxetine-treated neural stem cells was 
effectively blocked by both PI3K inhibitor (LY294002) and MEK inhibitor (PD98059). It was, therefore, 
suggested that the crosstalk between PI3K/Akt and MAPK/ERK pathways involved Akt and ERK1/2 
phosphorylation by fluoxetine treatment [70]. 
Glycogen synthase kinase 3 (GSK3) is a protein kinase that is primarily phosphorylated and 
inactivated by Akt [75] and several other protein kinases, such as PKC [76] and PKA [77]. GSK3 is a 
potential molecular target in several psychiatric disorders, particularly mood disorders, as the mood 
stabilizer lithium is a selective inhibitor of GSK3 [78,79]. Inhibition of GSK3 by pharmacological  
or genetic means mimics the effects of antidepressants [80,81] and anti-manic drugs [81,82],  
whereas impaired regulation of GSK3 results in behavioral abnormalities reminiscent of states of mania 
and depression [24,83]. 
Another relevant group of Akt substrates is the Forkhead box O transcription factors (FoxOs).  
In response to growth factors, active Akt phosphorylates and inactivates FoxOs by exporting them out 
of the nucleus [84]. In both invertebrate and vertebrate brain, FoxOs can be phosphorylated and 
inactivated by serotonin via the PI3K/Akt-dependent mechanism [85,86], and the FoxO3a subtype in 
brain can be inactivated by the antidepressant imipramine [86] and down-regulated by lithium [87].  
In addition, mice with FoxO deficiency exhibit antidepressive and anxiolytic behavioral phenotypes [86]. 
Therefore, regulation of protein substrates by Akt in brain plays a critical role not only in neuronal 
growth and survival, but also in the maintenance of neuronal activity and behavior. 
3.5. Na+/H+ Exchangers 
Na+/H+ exchangers (NHEs) are expressed in the surface of all mammalian cells, serving to regulate 
cell volume, intracellular pH, and transepithelial transport of Na+ and acid-base equivalents. It has been 
shown that microinjection of activated Ras or transfection of the Ha-Ras oncogene stimulates NHE 
activity in fibroblasts. The classical effect of GTP-bound Ras is the activation of the ERK1 and ERK2. 
This is thought to occur primarily through a linear signaling pathway including Ras-GTP → Raf-1 kinase 
→ MEK (MAPK/ERK kinase) → ERK [51]. Activation of 5-HT1A receptor resulted in the formation of 
a signaling complex that included activation of Janus kinase (JAK2), Ca2+/calmodulin (CaM) and NHE-1, 
and which involves tyrosine phosphorylation of CaM. It was thus proposed that NHE-1 activation 
proceeded through the pathway involving 5-HT1A receptor → G(i2)α and/or G(i3)α → Jak2 activation 
→ tyrosine phosphorylation of CaM → increased binding of CaM to NHE-1 → induction of 
conformational change in NHE-1 that unmasks an obscured proton-sensing and/or proton-transporting 
region of NHE-1 → activation of NHE-1 [88]. 
3.6. Nitric Oxide (NO) Production 
The 5-HT1A receptor can also regulate the production of NO in some circumstances. It is supposed 
that putative 5-HT1A receptor in rat ventral prostate cells can stimulate NOS activity [89]. In contrast,  
5-HT1A receptors inhibit N-methyl-D-aspartate (NMDA)-induced NO production in the adult rat 
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hippocampus and in human neocortical slices [83,90–92] suggesting that the regulation of NO synthesis 
by 5-HT1A receptor may be complex and cell-specific [21]. 
Various inhibitors of nitric oxide synthase (NOS) have been shown to exert antidepressant-like 
behavioral effect in a variety of animal models. Nitric oxide (NO) plays an important role in the brain, 
and pharmacological manipulations of the NO pathway will constitute a novel approach for therapeutic 
applications in the future [93,94]. It was recently found that the antidepressant-like effect of TRIM,  
a nNOS inhibitor, in the rat FST was partially attenuated by the depletion of endogenous serotonin (with 
the use of p-chlorophenylalanine). It was also suggested—on the basis of the experiments with different 
5-HT1 and 5-HT2 receptors antagonists)—that the antidepressant-like effect of TRIM was mediated, at 
least in part, by an interaction with 5-HT2 receptors while non-significant effects were obtained with  
5-HT1 receptors [95]. 
3.7. Diversity of 5-HT1A Pathways 
As already noticed, the 5-HT1A receptor has been found to regulate several channels and transport 
processes, as well as to activate AD in transfected cells and native tissues (for a review see [21]).  
In addition, a G protein-independent pathway of 5-HT1A receptor coupling to a smooth inward current 
(preceding calcium-dependent chloride current) Ismooth in Xenopus laevis oocytes was also suggested [96]. 
Raymond et al. recently addressed the question about the reasons behind the multiplicity of 5-HT1A 
receptor signaling. They suggested the ability to activate overlapping pools of G-proteins, activation of 
distinct signals emanating from G-protein α- and βγ-subunits, different repertoires of G-proteins and 
signaling enzymes expressed in cells, ratio of G-protein/effector/and receptor, ligand-specific effects, 
differential rates of desensitization, and cellular compartmentalization, to name just a few. It was 
suggested that the variables that affect the multiplicity of signaling from single receptor types are not 
likely to be manifested as “all or none” effects. The specific coupling of single types of 5-HT receptors 
to signaling pathways is likely to result from the summation of effects specific to the host cell milieu. 
One other theoretical possibility is that some signals emanating from 5-HT1A (or other 5-HT) receptors 
may be regulated by effector pathways activated through non-G-protein-activated pathways [1]. 
4. 5-HT1A Receptors and Depression 
4.1. Serotonin and Depression 
Serotonergic system has been implicated in affective illnesses, depression being induced by inhibitors 
of 5-HT synthesis [97] and tryptophan-depleting diets [98] and being alleviated in the response to  
SSRIs [99]. Acute tryptophan depletion has been shown to trigger relapse in recovered depressed  
patients and elicits a depressed mood in normal subjects, while most antidepressant treatments, including 
SSRIs, increase 5-HT neurotransmission either directly or indirectly. Further, chronic administration of 
paroxetine in rats with tryptophan depleted levels reduced depression-like behavior [100]. The effects 
of citalopram have been reported in several studies using rodent in behavioral assays, such as the tail 
suspension test (TST) and the FST, in which immobility is interpreted as an expression of behavioral 
despair or entrapment. In the TST, acute administration of citalopram dose-dependently reduced 
immobility of several mouse strains. In the FST, chronic administration of fluoxetine, another SSRI, 
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reversed the depressive-like behavior by decreasing immobility and increasing escape attempts of rats [101]. 
Similar effects were observed following fluoxetine directly infused within the raphe nuclei of mice [102]. 
Increases in the expression of a particular micro-RNA, named miR-16, has been detected following 
infusion of fluoxetine in the raphe nuclei, mimicking antidepressive-like behavior [102]. Interestingly, 
deep brain stimulation of the subthalamic nucleus in naive or dopamine-depleted rats decreased the firing 
rate of serotonergic neurons in DRN and enhanced immobility in the FST, which was counteracted by 
chronic administration of citalopram [103]. 
4.2. Role of Pre- and Postsynaptic 5-HT1A Receptors 
Various 5-HT receptor knockout strains have been developed to study the role of serotonin in 
modulating the stress response. 5-HT1A knockout mice exhibit anxiety-like behaviors, lower 
hypothalamic-pituitary-adrenal (HPA) response rates, and have reduced adrenal gland weight [104]. 
Consistently, a transgenic line overexpressing the murine 5-HT1A receptor in the central nervous  
system under control of its endogenous promoter had reduced anxiety. The transgenic mice revealed 
typical phenotypic changes indicative of 5-HT1A receptor overactivity—a reduced molar ratio of  
5-hydroxyindoleacetic acid to 5-HT in several brain areas and elevated serotonin levels in the 
hippocampus and striatum [105]. Additionally, mice with complete 5-HT1A receptor knockout (KO), 
lacking both auto- and heteroreceptors through life, consistently showed increased anxiety in  
conflict-based anxiety paradigms tasks, while exhibiting decreased behavioral despair in response to 
stress (higher mobility time in the FST and TST), suggesting that the absence of 5-HT1A receptors could 
result in an “antidepressant-like” effect [14,106–109]. Since behavioral despair in response to stress is 
decreased by acute treatment with a number of drugs used to treat depression, this phenotype has been 
referred to as “antidepressed” [13]. 
Günther et al. [110] examined the impact of postsynaptic 5-HT1A-receptor overexpression in 
corticolimbic areas (which are thought to be part of the neuronal circuitry of depression [111]) of male 
and female mice (with female mice displaying higher receptor binding in the distinct brain areas) on the 
performance in the FST and suggested the involvement of postsynaptic 5-HT1A-receptors in the effects 
of SSRIs. In the FST untreated male, but not female, overexpressing mice showed an antidepressant-like 
behavior compared to wild-type mice. Citalopram yielded an antidepressant effect without influencing 
locomotor activity in overexpressing male but not in wild-type mice. Reboxetine (norepinephrine 
reuptake inhibitor—NRI) had no antidepressant-like effect in overexpressing mice, but a sex dependent 
effect in WT mice (antidepressant-like response in female mice). The two partial agonists, buspirone 
and S 15535, produced no antidepressant-like activity in both genotypes and sexes, but gave aberrant 
motor effects [110]. 
It was shown in the transgenic mice model, allowing to independently assess the function of 5-HT1A 
autoreceptors and heteroreceptors, that suppression of endogenous heteroreceptors was not sufficient to 
impact anxiety-like behavior [14,112]. Furthermore mice lacking 5-HT1A heteroreceptors throughout  
the life displayed decreased mobility in the FST, or increased behavioral despair, in adulthood [14]. 
Suppression of the 5-HT1A heteroreceptors during development leads to an increased behavioral despair 
in adulthood. In contrast, this phenotype was not observed when heteroreceptor suppression was initiated 
in adulthood, suggesting that 5-HT1A heteroreceptors act developmentally to establish the circuitry 
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underlying the behavioral response to forced swim stress without affecting conflict-based anxiety 
paradigms [112]. It was thus concluded that suppression of 5-HT1A heteroreceptors results in behavioral 
despair, but not anxiety, while ectopic overexpression in the forebrain of this receptor during 
development rescues the anxious phenotype of whole brain 5-HT1A KO mice [14] (Table 1). 
Richardson-Jones et al. [13] elaborated a murine model in which it was possible to specifically 
modulate 5-HT1A autoreceptor levels without affecting heteroreceptor levels. Transgenic strains with 
high (1A-high) and low (1A-low) 5-HT1A autoreceptor densities were obtained. 1A-high (but not 1A-low) 
mice displayed the expected dose-dependent hypothermic response to the 5-HT1A agonist, 8-OH-DPAT. 
Between mice with low and high 5-HT1A autoreceptor levels no differences in the open field paradigm 
and the light/dark choice test were observed. Additionally, between 1A-low and 1A-high mice no 
differences in the TST and FST were observed. However, in the FST 1A-high, but not 1A-low, displayed 
progressively less mobility or more behavioral despair, upon re-exposure on the second day. Following 
four weeks of repeated stress, 1A-high and 1A-low mice remained indistinguishable in their total 
exploration in the open field. However, 1A-high, but not 1A-low mice, displayed less mobility in FST 
and TST. Thus, while decreasing adult levels of 5-HT1A autoreceptors does alter either conflict-based 
anxiety or behavioral response to an acute stressor, it results in increased physiological reactivity to 
stress and appears to elicit a more active response to a repeated stress in a depression-related task 
(reduced depression-like behavior) [13]. The 1A-low, but not 1A-high, responded to 26 days of 
fluoxetine treatment in the novelty suppressed feeding paradigm (measuring the latency of a mouse to 
consume food placed in the middle of a brightly lit, aversive arena). On this basis it was suggested that 
a decrease in 5-HT1A autoreceptor levels in adulthood, prior to antidepressant treatment, is sufficient to 
confer responsiveness to fluoxetine in an otherwise treatment-resistant population [13]. It was shown 
that loss of autoreceptors impacts anxiety in the adult, suggesting that the anxious-like phenotype  
of the 5-HT1A KO mouse likely results from increased serotonergic signaling from a disinhibited  
raphe [13,14,112]. Donaldson et al. found that decreases in 5-HT1A autoreceptors during development 
(postnatal days P14-P30, with a maximal reduction of 40% at P21 and return to regular levels by P30) 
leads to a long-term increases in anxiety levels and decreases levels of social engagement, but does not 
alter depression-like behaviors [113]. Similarly, it was shown that suppression of endogenous 5-HT1A 
autoreceptors throughout life is sufficient to increase anxiety-like behavior in the adult [112] and does 
not impact behavior in the FST in adulthood [14]. However, modulating 5-HT1A autoreceptors in 
adulthood does not impact anxiety-like behavior and results in lower levels of depression-related 
behaviors [13,114] (Table 1). 
On the basis of their results [14] Garcia-Garcia et al. suggested the distinct roles of the two 
endogenous receptor populations mediating anxious or depression-like phenotypes with autoreceptors 
impacting the establishment of anxiety-like behavior and with heteroreceptors affecting behavior in  
the FST, a depression-related test [14]. Different roles of pre- and postsynaptic 5-HT1A receptors  
was suggested by Albert et al. who suggested that reduced activity of post-synaptic 5-HT1A receptor is 
implicated in anxiety, while an increased transcription of 5-HT1A autoreceptor associates with depression 
and resistance to chronic SSRI treatment [115]. Consistently, reduced expression of presynaptic 5-HT1A 
receptors - without altering postsynaptic 5-HT1A receptors was sufficient to evoke antidepressant-like 
effects in mice [13,116,117] (Table 1). 
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Table 1. Relationship between 5-HT1A receptor density and behavioral effects. 
Behavioural Effect Auto- and Heteroreceptors Autoreceptors Heteroreceptors 
Whole life knockout [13,14,104,106–109,112] 
Anxiety  Elevated Elevated No impact 
Depression  Lower No impact Elevated 
Knock-down between 14 and 30 days (40%) [113] 
Anxiety - * Long-term increase - 
Depression - No effect - 
Adulthood [9,13,114] 
Anxiety - No effect - 
Depression - Diminished - 
Reduced activity    
Anxiety - - Elevated [115] 
Depression - Diminished [13,116,117]  - 
Overexpression 
Anxiety Diminished [105,118] - - 
Depression - Elevated [110] - 
Increased transcription 
Depression - Increased [115] - 
* No data. 
An interesting conclusion may be drawn from two novel 5-HT1A receptor agonists F15599 [55] and 
F13714 [119]. Detailed analysis of their in vitro, in vivo, electrophysiological, and neurochemical profile 
indicate that, contrary to F13714, F15599 preferentially activates post- versus pre-synaptic 5-HT1A 
receptors [120] and influences frontal cortex pyramidal neuron electrical activity at doses that are an 
order of magnitude lower than those that inhibit raphe neuron electrical activity [121]. The compounds 
exhibited a potent (similar) activity in the FST and in conditioned stress-induced ultrasonic vocalization 
in rats, despite the fact that F13714 had an in vitro potency ca. two orders of magnitude greater than 
F15599 (Ki 5-HT1A CHO cells 10.40 and 8.57, respectively) and substantial activity of F13174 at 
presynaptic 5-HT1A receptors [122]. Additionally, F15599 had a remarkable capacity (as compared to 
F13714) to reverse phencyclidine (non-competitive antagonist of NMDA-glutamatergic receptors) 
induced memory/cognition deficits and had a lower propensity than F13714 to induce serotonergic 
syndrome (lower lip retraction, forepaw treading, flat body posture) [122]. F15599 exhibited lower than 
F13714 efficacy for ERK phosphorylation (pEC50 7.81 and 9.07, respectively) and cAMP accumulation 
inhibition (pEC50 6.46 and 8.67, respectively). Both compounds activated Gαi and Gαo subunits in  
HeLa-h5-5-HT1A cell membranes, although with different efficacy. It was, thus, suggested that distinct 
signaling profiles (Figure 4) and functional selectivity for specific receptor activation responses of 
F15599 underlined its favorable pharmacological profile [55]. It is, however, to be determined which 
transduction pathway—Activation of pre- or post-synaptic 5-HT1A receptors, ERK phosphorylation, 
cAMP inhibition, Gαi or Gαo activation—Is connected to a particular behavioral syndrome. Interestingly, 
activation of presynaptic 5-HT1A receptors does not influence F13174 antidepressant activity,  
as compared to F15599. 




Figure 4. Pharmacological profile (pEC50 for cAMP inhibition and ERK1/2 phosphorylation 
on the Y axis) of F15599 (brown), F13714 (green), and 5-HT (dark blue) [55]. 
4.3. Antidepressant Treatment and 5-HT1A Receptors 
According to pharmacological studies, pre-synaptic and post-synaptic 5-HT1A receptor activation 
appears to be involved in anxiolytic and antidepressant effects, respectively [9]. Alterations in 5-HT1A 
receptor levels are commonly observed in depressed individuals. Reduced somatodendritic and 
postsynaptic 5-HT1A receptor numbers or affinity have been reported in some post-mortem studies of 
suicide victims, a result consistent with well-replicated positron emission tomography (PET) analyses 
demonstrating reduced 5-HT1A receptor binding potential in diverse regions such as the dorsal raphe, 
medial PFC, amygdala, and hippocampus [123]. 
Post-synaptic 5-HT1A receptors are reduced in several cortical regions in depression and anxiety, 
while 5-HT1A autoreceptors are increased in depression. Elevated 5-HT1A autoreceptor expression would 
tend to reduce the activity of 5-HT neurons, while reduced post-synaptic 5-HT1A receptors would result 
in a blunted behavioral response to 5-HT [10,14]. Hence, post-mortem and genetic studies have shown 
that individuals with elevated density or activity of 5-HT1A-autoreceptors were more susceptible to mood 
disorders and suicide, and respond poorly to antidepressants [124–126]. However, PET studies using 
[11C]-WAY-100635 to label 5-HT1A receptors have shown no case-control differences, increases, nor 
decreases of the binding potential of 5-HT1A receptors in major depressive disorder (MDD) patients.  
A lowered 5-HT1A receptor binding potential has also been found in recovered major depressives 
compared to controls, which has led to the suggestion that a low 5-HT1A receptor density may confer 
vulnerability to MDD [2]. In this regard, MDD may be associated with a reduced post-synaptic 5-HT1A 
receptor-mediated function, as suggested by PET scan studies [122,127], although this abnormality 
persists after clinical remission [128]. 
Rodent studies have shown that pre-synaptic 5-HT1A (and to a lower extent, 5-HT1B) autoreceptors 
play a major detrimental role in antidepressant treatments, due to the activation of negative feedback 
mechanisms operating in 5-HT neurons following the increase in extracellular 5-HT evoked by SERT 
blockade. Hence, excitatory inputs increase 5-HT release in the midbrain raphe. The excess 5-HT 
activates dendritic 5-HT1A autoreceptors, hyperpolarizes 5-HT neurons and, thus, opposes the incoming 
excitatory inputs. Antidepressant drugs evoke a pharmacological overactivation of this physiological 
feedback mechanism by markedly increasing extracellular 5-HT in the raphe nuclei (which contain  
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by SSRI and selective NRI (and by monoaminooxidase inhibitors) reduces serotonergic activity and  
5-HT release in forebrain, thereby attenuating the 5-HT elevation produced by SERT blockade in  
corticolimbic networks thus limiting the activation of postsynaptic 5-HT receptors responsible for 
clinical antidepressant effects [2,129]. Recent observations with PET suggest the existence of a similar 
negative feedback mechanism in primate and human brains. Thus, a single, clinically-relevant dose of 
escitalopram increased 5-HT release in the raphe nuclei and reduced it in the projection areas [130]. 
This negative feedback mechanism is involved in the delayed action—and possibly, limited efficacy—of 
antidepressant drugs. The preferential blockade of presynaptic 5-HT1A receptors by pindolol (mixed  
β-adrenoceptor/5-HT1A receptor antagonist) accelerates the clinical effects of SSRIs [131–133].  
Pindolol partially blocks the SSRI-induced, 5-HT1A receptor-mediated negative feedback and augments 
forebrain 5-HT release, mimicking the 5-HT1A autoreceptor desensitization produced by chronic 
antidepressant treatment [134]. 
Chronic treatment with antidepressant drugs desensitizes pre-synaptic 5-HT1A autoreceptors, which 
reduces the efficacy of the autoreceptor-mediated negative feedback and enables a normalization of  
5-HT release, thus allowing a greater activation of postsynaptic 5-HT receptors responsible for clinical 
antidepressant action. 
Studies in rats treated chronically with SSRIs have shown an initial decrease of raphe firing at the 
beginning of treatment, with firing rates recovering to baseline following chronic treatment and 5-HT1A 
autoreceptor desensitization [135]. The long time required for SSRIs’ clinical efficacy onset (several 
weeks) may be attributed to the necessity of 5-HT1A autoreceptor desensitization or/and to the time 
required to evoke plastic changes in certain brain areas involving protein synthesis or trophic actions. 
Additionally, repeated treatment with 5-HT1A agonists desensitizes pre-synaptic 5-HT1A receptors in the 
raphe nuclei, which disengages 5-HT neurons from autoreceptor-mediated inhibition. As a consequence, 
5-HT neurons are activated by chronic treatment with 5-HT1A agonists, and this counteracts the 5-HT 
deficit in depression [136,137]. 5-HT1A antagonist can improve the efficacy of SSRIs by either blocking 
inhibitory 5-HT1A autoreceptors or could have antidepressant-like activity by triggering post-synaptic  
5-HT1A receptors and/or producing a faster desensitization of 5-HT1A autoreceptors. In line with this,  
the selective inactivation of presynaptic 5-HT1A receptors by genetic or molecular means (siRNA) is 
sufficient to evoke robust antidepressant-like effects in rodents [9]. 
Several 5-HT1A receptor agonists show antidepressant activity in various animal models, such as  
TST and FST [135,138]. 5-HT1A receptor KO mice display increased anxiety-related behavior, which,  
unlike in their wild-type counterparts, cannot be rescued with antidepressant drug treatment [123].  
The activation of post-synaptic hippocampal 5-HT1A receptors plays an important role in MDD. Chronic 
antidepressant treatments tonically activate hippocampal 5-HT1A receptors [123,135]. Furthermore, 
genetic studies indicate that post-synaptic 5-HT1A receptors are sufficient for antidepressant-like effects 
in rodents [112]. Antidepressant effects of some 5-HT1A drugs may be attributed to the activation of 
post-synaptic 5-HT1A receptor sites, an effect likely linked to their therapeutic action [139,140]. Lithium, 
valproate, SSRIs, tricyclic antidepressants (TCAs), and other treatments, such as electroconvulsive 
shock therapy, all increase post-synaptic 5-HT1A receptor signaling through either direct or indirect 
effects [123]. These observations, together with the antidepressant properties of 5-HT1A agonists in 
preclinical tests, have led to the suggestion of post-synaptic 5-HT1A agonists as a new class of 
antidepressants [135]. Most 5-HT1A agonists developed so far—and in particular, the azapirones—show 
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full agonist properties at pre-synaptic 5-HT1A autoreceptors and are partial agonists at post-synaptic  
5-HT1A receptors, which results in a reduced tone on post-synaptic 5-HT1A receptors after the 
administration of 5-HT1A agonists [2]. Under conditions of increased serotonin release, the occupancy 
of post-synaptic 5-HT1A receptors by a partial agonist may actually reduce 5-HT1A receptor transmission 
by blocking the direct effects of serotonin while inducing only a partial agonist effect instead [122]. 
Despite the initial hopes placed on the clinical use of 5-HT1A receptor agonists as antidepressant 
drugs, these agents achieved little clinical success, partly due to their limited clinical efficacy and to the 
widespread occurrence of gastrointestinal side effects. Several azapirones, such as buspirone, gepirone, 
ipsapirone or tandospirone, showed antidepressant-like efficacy in preclinical studies, and clinical 
efficacy in open-label or placebo-controlled trials. The failure of azapirones in MDD may be related to 
their preferential presynaptic activity [135,141]. Classical 5-HT1A receptor agonists, and particularly 
azapirones (buspirone, gepirone, etc.) are full agonists at raphe 5-HT1A receptors and partial agonists at 
post-synaptic hippocampal 5-HT1A receptors [142]. However, some new agents with chemical structures 
different from the azapirones (e.g., F15599) display preferential agonist actions at post-synaptic 5-HT1A 
receptors [55,143]. 
5-HT1A receptor antagonists may improve the clinical effects of antidepressants by preventing the  
5-HT1A autoreceptor-mediated negative feedback [144]. The antagonists may thus mimic the 5-HT1A 
autoreceptor desensitization effect of chronic SSRIs administration, thus augmenting the effect of SSRIs 
on forebrain extracellular 5-HT concentration. In this respect, selective antagonists, preferentially 
blocking pre-synaptic vs. post-synaptic 5-HT1A sites, would be required [2,145,146]. 
It was suggested [9] that 5-HT1A partial agonism, combined with 5-HT reuptake inhibition, can 
produce antidepressant-like effects. These observations have led to the development of new 
antidepressant drugs blocking the serotonin transporter (SERT) and having partial agonist activity at 5-HT1A 
receptors, in order to evoke a higher increase in extracellular 5-HT: Vilazodone, approved in 2011 by 
the FDA for use in the treatment of MDD, and vortioxetine (LuAA21004, in development) [147,148]. 
Similarly flibanserin, DU-125530, and OPC-14523 have reached late stage clinical development as 
antidepressant drugs [9]. 
Mayorga et al. showed that fluoxetine and paroxetine failed to ameliorate immobility behavior in  
5-HT1A KO mice exposed to a stressor, suggesting that 5-HT1A receptor activation is a necessary feature 
of the antidepressive response [149]. It was, however, shown that 5-HT1A KO mice respond to TCAs,  
but not to the SSRI fluoxetine, in the TST and the novelty-suppressed feeding test, suggesting that the 
5-HT1A receptors are a critical component in the mechanism of action of SSRIs, but not TCAs [148,150]. 
It should also be noted that according to clinical data, full 5-HT1A blockade neither enhances nor cancels 
the antidepressant effect of fluoxetine in MDD patients [139], suggesting the involvement of other 5-HT 
receptors (e.g., 5-HT4 receptor) [151]. 
Recent studies suggested that neurogenesis is involved in the action of antidepressants [152]. 
Neurogenesis, the process of neuronal stem cell proliferation, differentiation and survival, has also been 
thought to occur in humans, at a slow, but detectable rate [150]. Santarelli et al. [153] demonstrated  
the involvement of antidepressants in adult hippocampal neurogenesis. In addition, this study showed 
that 5-HT1A knockout mice did not exhibit neurogenesis or respond behaviorally to SSRI treatment, 
implicating these receptors in antidepressant-mediated neurogenesis. The antidepressant effects of 5-HT1A 
receptor stimulation may be related to the induction of hippocampal neurogenesis, a common feature of 
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antidepressant treatments [154], which depends on 5-HT1A receptor activation [150], but also the 
functional remodeling of corticolimbic circuits involved in MDD [122]. It was thus suggested that the 
treatment with antidepressants could lead to adaptive changes such as neurogenesis over a period of 
weeks, which may account for the delayed therapeutic effect of these drugs [155]. 
As with the 5-HT1A receptors, acute SSRI administration activates terminal 5-HT1B receptors,  
thus reducing 5-HT synthesis and release. Likewise, chronic administration of SSRI also results in 
desensitization of terminal 5-HT1B autoreceptors, suggesting that plasticity in both the 5-HT1A- and  
5-HT1B-mediated autoregulatory function may be important in the therapeutic profile of SSRI [156,157]. 
Moreover, as observed with 5-HT1A receptors, the administration of 5-HT1B receptor antagonists 
augments the neurochemical and behavioral effects of SSRI [158,159]. The effects of SSRIs have  
also been analyzed in genetic rodent models of depressive-like behaviors, such as in mice lacking the  
5-HT1B receptor. The acute administration of citalopram or paroxetine failed to decrease the immobility 
in the FST of the 5-HT1B (KO) compared to WT mice, suggesting that antidepressant effects of  
SSRI depend on activation of the 5-HT1B receptor [6]. Interestingly, the effects of 5-HT1B antagonists 
on pre-synaptic 5-HT function are additive to those of 5-HT1A antagonists, indicating a diversity of 
mechanisms to augment the effects of SSRI [160]. Mice lacking both 5-HT1A/1B autoreceptors exhibit an 
increased 5-HT transmission also associated to anxiety-like behavior. While acute paroxetine failed to 
reverse anxiety-like behavior, its chronic administration still led to anxiolytic effects in the elevated  
plus maze [6]. 
5. Models of Depression Involved Circuits 
The current limitation of SSRI/SNRI treatments most likely derives from the poor knowledge of the 
pathophysiology of major depression, in common with other psychiatric disorders. The lack of a unifying 
theory on the cause of depression, together with the partial success of antidepressant drugs enhancing 
serotonergic (and to a lesser success, noradrenergic) function, has dominated the antidepressant drug 
development so far. Numerous clinical and preclinical studies indicate that disturbances in serotonergic 
activity may be associated with major depression. Noradrenergic and dopaminergic neurotransmission 
has also been implicated, although the exact changes in these monoamine systems are unknown. 
Historically, a functional hypoactivity of these systems has been assumed in depression. This view was 
mainly based on the observation that antidepressant drugs increase monoaminergic function (particularly 
serotonin and norepinephrine). One commonality of these ascending monoaminergic systems is that  
their cell bodies are located in the brain stem and that their activity is tightly controlled by the PFC,  
a cortical area where metabolic abnormalities have been reported in depressive patients. Thus, the  
raphe nuclei, the locus coeruleus, and the ventral tegmental area, where the cell bodies of ascending 
serotonergic, noradrenergic, and dopaminergic neurons are located, respectively, receive dense afferents 
from dorsal and ventral parts of the medial PFC in rodents, which are equivalent to dorsal and ventral 
cingulate are as in primate and human brain. The treatment with antidepressant drugs would restore 
monoamine function in cortical and limbic areas, thus improving depressive symptoms. Based on these, 
Artigas has shown a schematic representation (not included) of the functional connectivity between the 
medial prefrontal cortex and the dorsal and median raphe nuclei of the midbrain [2]. 
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Albert et al. proposed a simplified model of raphe and PFC circuitry involvement in anxiety and 
depression (Figure 5) [161]. It was suggested that there are two major sub-populations of heteroreceptors 
in PFC: 5-HT1A receptors on pyramidal glutamatergic neurons and on GABA interneurons that inhibit 
the activity of both neuron types [162]. In rodent PFC, ~50% of pyramidal neurons and ~25% of 
GABAergic interneurons express 5-HT1A receptors [163], and this proportion is even higher (up to 80%) 
in upper cortical layers of primate and human PFC [162]. It should also be noted that 5-HT1A receptors 
are abundantly coexpressed (in ca. 80%) with excitatory 5-HT2A receptors in rodent PFC [161]. 5-HT2A 
receptors have 10-fold lower affinity for 5-HT and with maturation 5-HT1A receptor inhibition 
predominates over 5-HT2A excitatory function. In this model the activity of the GABA interneurons 
exhibits inhibitory activity on glutamatergic pyramidal neurons while 5-HT1A heteroreceptors diminish 
the GABAergic activity. In the anxiety model, under normal conditions both 5-HT1A heteroreceptors on 
pyramidal and interneurons are engaged, resulting in a balance between 5-HT1A-mediated inhibition and 
dys-inhibition on pyramidal neurons. On the basis of evidence from human imaging studies, it was 
suggested that different sub-populations of PFC neurons with different targets mediate anxiety vs. 
depression behavior. Due to these differences, the serotonin circuitry model for depression involves 
similar components but is slightly different from the anxiety model. First, opposite to anxiety, activation 
of the pyramidal neuron is associated with reduced depression and increased resilience. Second, it was 
proposed that the 5-HT2A receptor is weakly active in the mature pyramidal neurons controlling 
depression. The model predicts elevated anxiety at the low and high serotonin levels and elevated 
depression at the lack of serotonin and its low levels [162]. 
 
Figure 5. Adult 5-HT raphe-PFC circuitry in anxiety and depression model (according to 
Albert et al.) [161]. The model shows 5-HT neurons (brown) projecting to prefrontal cortex 
GABAergic interneurons (yellow) and glutamatergic pyramidal neurons (blue) with transmitter 
release illustrated as small circles of the same colors. Receptors: 5-HT1A (green), 5-HT2A 
(light green), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-glutamate 
(purple) and GABAA receptors (blue). The response in the target neurons (red ovals): 
stimulatory (+), inhibitory (−). (↑)—elevation, (↓)—decrease. 5-HT1A heteroreceptors and 
GABAA receptors reduce the activity of the pyramidal neurons while 5-HT2A receptors 
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The model was shown to fit with the genetic model where mutants with reduced or eliminated 5-HT 
show depression phenotypes, while suppression of 5-HT1A autoreceptors in adults to increase the 5-HT 
activity reduces depressive behavior. Reduced interneuron 5-HT1A receptors would enhance interneuron 
firing and inhibit pyramidal firing, leading to a depression phenotype similar to the low or no 5-HT 
condition. Suppression of pyramidal 5-HT1A heteroreceptors (using the CaMKIIα promoter to target 
pyramidal neurons) would be predicted to increase pyramidal neuron firing and display an anxiety 
phenotype rather than depression. Over-expression of 5-HT1A autoreceptors would reduce 5-HT activity 
leading to a hyperactive anxiety circuit by preferentially relieving inhibition of pyramidal neurons.  
On the other hand, global knockout of all 5-HT1A receptors would allow for hyper-activation of raphe 
neurons (due to absence of 5-HT1A autoreceptor) and activation of stimulatory pyramidal 5-HT2A 
receptors that is not antagonized by pyramidal 5-HT1A receptors, leading to increased anxiety.  
Pyramidal 5-HT2A receptor activation may also actively suppress interneuronal GABA-mediated 
inhibition via activation of protein kinase C. Consistent with a pro-anxiety role, mice lacking 5-HT2A 
receptors display reduced anxiety that is reversed by cortical re-expression of 5-HT2A receptors [162]. 
It was shown that numerous antidepressants and antipsychotic drugs bind with relatively high affinity 
at 5-HT2A receptors and several clinical studies have shown that atypical antipsychotics augment the 
clinical response in treatment-resistant patients. The effect was suggested to be due to their ability to 
occupy 5-HT2 receptors, and more specifically to block 5-HT2A-mediated response. The increased 
extracellular 5-HT concentration produced by SERT blockade activates excitatory 5-HT2A receptors and 
inhibitory 5-HT1A receptors (Figure 6A). Given the large co-expression of 5-HT1A and 5-HT2A receptors 
in the neocortex [164] blockade of 5-HT2A receptors (or atypical antipsychotic drugs) blocks excitatory 
effects of 5-HT on pyramidal neurons. That may enhance inhibitory 5-HT1A receptor-mediated 
neurotransmission in cortical and limbic areas, an effect likely linked to the antidepressant activity 
(Figure 6B). This effect may reduce a potential hyperactivity in ventral cingulate areas and normalize 
the functional connectivity between ventral and dorsal PFC areas and with limbic areas and monoamine 
systems [2]. 
 
Figure 6. The potential mechanism underlying the augmenting effects of 5-HT2A receptor 
blockade. (A) Increased extracellular 5-HT concentration may activate limbic monoamine 
system; (B) Blockade of activating 5-HT2A receptors may reduce a potential hyperactivity of 
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Bevilacqua et al. have suggested a functional interaction between SERT and the 5-HT2B receptor—a 
receptor implicated in 5-HT-dependent phenotypes, including impulsivity, aggressivity and suicidality [165]. 
Ex vivo studies have indicated that 5-HT2B receptors might participate in the control of SERT in raphe 
neurons [166], while in vivo studies further confirmed that 5-HT2B receptors contribute to the behavioral 
and physiological effects of the SERT-targeting 5-HT releasers, 3,4-methylenedioxymethamphetamine 
(MDMA, the club-drug ecstasy) and dexfenfluramine [167–169]. Diaz et al. [170] reported that the  
acute response to SSRIs in the FST, a classical test for antidepressant activity, is absent in mice lacking  
5-HT2B receptors. Conversely, a 5-HT2B receptor agonist induced an antidepressant-like action in the 
FST, suggesting that this receptor is required for acute SSRI effects and might modulate serotonergic 
tone. It was also shown that long-term behavioral and neurogenic SSRI effects were abolished  
after either genetic or pharmacological inactivation of 5-HT2B receptors. Conversely, direct agonist 
stimulation of 5-HT2B receptors induced an SSRI-like response in behavioral and neurogenic assays 
suggesting that antidepressant effects of SSRI depend on activation of the 5-HT2B receptor [169,171]. 
Another candidate for mediating the antidepressant-like effects of SSRIs is the 5-HT2C receptor.  
5-HT2C receptor agonists show antidepressant-like effects in multiple animal models (both acute and 
chronic) of depression [172]. For example, 5-HT2C receptor agonists decrease immobility time and 
increase swimming time in the FST in rats in a manner comparable to SSRIs. The effects of the 5-HT2C 
receptor agonists and SSRIs in the rat forced swim test are antagonized by the 5-HT2C antagonists [173] 
consistent with the role for 5-HT2C receptors in mediating antidepressant-like effects of 5-HT2C receptor 
agonists and SSRIs (recently Rosenzweig-Lipson et al. have shown that novel 5-HT2C receptor agonist 
WAY-163909 exhibited antidepressant-like effects in rodents). 
6. Conclusions 
5-HT1A receptors have, for long time, been considered as interesting targets for antidepressant drugs. 
It was thus postulated that postsynaptic 5-HT1A agonists could form a new class of antidepressant drugs. 
It was also stated that most 5-HT1A agonists developed so far—and in particular, the azapirones—show 
full agonist properties at pre-synaptic 5-HT1A autoreceptors and are partial agonists at post-synaptic  
5-HT1A receptors, which results in a reduced tone on post-synaptic 5-HT1A receptors after the 
administration of 5-HT1A agonists. 
There is a, more or less, consistent view concerning the role of 5-HT1A receptors in depression  
and anxiety, with autoreceptors impacting the establishment of anxiety and heteroreceptors affecting 
depression-like tests. Results with 5-HT1A receptor KO animals have shown that 5-HT1A receptor  
KO mice exhibit increased anxiety-like behavior and decreased levels of depression. In line with that  
5-HT1A receptor overexpressing mice exhibit reduced anxiety. It was shown that 5-HT1A autoreceptor  
down-regulation resulted in antidepressant-like effects, and increased transcription was associated with 
depression, resistance to chronic SSRIs treatment, and mice lacking heteroreceptors throughout life 
exhibited increased levels of depression. 
It was suggested that the anxious-like phenotype of the 5-HT1A KO mouse likely results from 
increased serotonergic signaling from a disinhibited raphe. While decreasing adult levels of 5-HT1A 
autoreceptors does alter either conflict-based anxiety or behavioral response to an acute stressor, it may 
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result in increased physiological reactivity to stress and appears to elicit more active responses to a 
repeated stress in a depression-related task (reduced depression-like behavior). 
It was shown, that although 5-HT1A KO mice do not respond to the SSRI fluoxetine, they respond to 
TCAs (TST and the novelty-suppressed feeding test), suggesting that the 5-HT1A receptors are a critical 
component in the mechanism of action of SSRIs, but not TCAs. According to clinical data, full 5-HT1A 
blockade neither enhances nor cancels the antidepressant effect of fluoxetine in MDD patients suggesting 
the involvement of other 5-HT receptors (e.g., 5-HT4 receptor). 
Agonist-directed trafficking for 5-HT1A receptor signaling exists in rat native brain tissue. Thus,  
the receptors have the ability to activate overlapping pools of G-proteins, activate distinct signals 
emanating from G-protein α- and βγ-subunits and differing repertoires of G-proteins and signaling 
enzymes expressed in cells. It may express different ratios of receptor/G-protein/effector, ligand-specific 
effects, differential rates of desensitization, and cellular compartmentalization, as well as activate 
effector pathways through non-G-protein-activated pathways. The human 5-HT1A receptors, located in 
different brain regions despite similar [3H]-8-OH-DPAT binding profiles, present a different functional 
pharmacology. Moreover, receptor trafficking appears different at pre- and post-synaptic sites, with  
pre-synaptic 5-HT1A receptors showing more marked adaptive processes, including desensitization and 
down-regulation [156,174,175]. 
The 5-HT1A receptor may still be considered as valuable target for antidepressant drugs. New  
mixed 5-HT1A receptor ligands/SERT inhibitors seem to possess interesting pharmacological profiles. 
Although identifying the real molecular and brain-specific target for 5-HT1A receptor ligands may be a 
very complicated task due to the receptor signal transduction pathway complexity, it may result in better 
targeting, raising hope for more effective medicines for various pathologies. 
It should also be noted that 5-HT1A receptor cooperates with other transduction systems (like 5-HT1B 
and 5-HT2A/2B/2C receptors, GABA, glutamine) with relying its antidepressant and/or anxiolytic activity. 
Most probably additional serotonergic targets like 5-HT1B, 5-HT2B or 5-HT4-7 receptors should also be 
considered. 5-HT1B receptor antagonists administered alone or with antidepressants have been shown  
to be effective in preclinical models of depression; the activation of 5-HT1B heteroceptors induces 
antidepressant-like behavior. As with the 5-HT1A receptors, acute SSRI administration activates terminal 
5-HT1B receptors, thus reducing 5-HT synthesis and release. Likewise, chronic administration of SSRI 
also results in desensitization of terminal 5-HT1B autoreceptors, suggesting that plasticity in both the  
5-HT1A- and 5-HT1B-mediated autoregulatory function may be important in the therapeutic profile  
of SSRI. Mice lacking both 5-HT1A/1B autoreceptors exhibit an increased 5-HT transmission also 
associated to anxiety-like behavior. 5-HT2B receptors are also expressed by raphe serotonergic neurons.  
SSRI-induced increase in hippocampal extracellular 5-HT concentration is strongly reduced in the 
absence of functional 5-HT2B receptors and selective 5-HT2B agonists may mimic SSRI responses.  
5-HT2B receptors were shown to be required for the therapeutic actions of SSRIs. 5-HT4-7 receptors are 
also considered as new molecular targets for antidepressant drugs. 
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